Core Viewpoint - Ocugen, Inc. has successfully closed an underwritten registered direct offering of 15 million shares at $1.50 per share, resulting in net proceeds of $20.85 million, aimed at supporting its operations and extending its cash runway into Q4 2026 [1][2]. Group 1: Offering Details - The offering consisted of 15,000,000 shares priced at $1.50 each, leading to net proceeds of $20.85 million after expenses [1]. - The financing was led by RTW Investments, with participation from both new and existing investors [1]. - Oppenheimer & Co. served as the sole book-running manager for the offering [2]. Group 2: Use of Proceeds - The net proceeds will be allocated for general corporate purposes, capital expenditures, working capital, and administrative expenses [2]. - The funding is expected to extend the company's cash runway into the fourth quarter of 2026 [2]. Group 3: Company Overview - Ocugen, Inc. is a biotechnology leader focused on gene therapies for blindness diseases, utilizing a modifier gene therapy platform to address complex diseases caused by multiple gene network imbalances [5]. - The company is developing programs for inherited retinal diseases and blindness conditions affecting millions globally, including retinitis pigmentosa, Stargardt disease, and geographic atrophy [5].

Core Viewpoint - Ocugen, Inc. has announced the pricing of an underwritten offering of 15 million shares of common stock at $1.50 per share, aiming for gross proceeds of $22.5 million, expected to close around January 22, 2026 [1]. Group 1: Offering Details - The offering consists of 15,000,000 shares priced at $1.50 each, resulting in gross proceeds of $22.5 million before expenses [1]. - The offering is led by RTW Investments, with participation from both new and existing investors [1]. - Oppenheimer & Co. is the sole book-running manager for the offering [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for general corporate purposes, capital expenditures, working capital, and general and administrative expenses [2]. Group 3: Company Overview - Ocugen, Inc. is a biotechnology leader focused on gene therapies for blindness diseases, with a modifier gene therapy platform aimed at addressing significant unmet medical needs [5]. - The company is developing programs for inherited retinal diseases and blindness diseases, including retinitis pigmentosa, Stargardt disease, and geographic atrophy [5].

Core Insights - Ocugen, Inc. is a biotechnology leader focused on gene therapies for blindness diseases and aims to present significant progress at the upcoming NobleCon21 conference [1][2][4] - The company is targeting three Biologics License Applications (BLAs) within three years and plans to discuss near-term catalysts for 2026 during the conference [2][4] Company Overview - Ocugen's modifier gene therapy platform addresses complex diseases caused by imbalances in multiple gene networks, offering a gene-agnostic approach [4] - Current development programs include treatments for inherited retinal diseases and blindness diseases such as retinitis pigmentosa, Stargardt disease, and geographic atrophy [4] Conference Details - Dr. Shankar Musunuri will present on December 3, 2025, at 1 p.m. ET, with a focus on the company's scientific platform and clinical development strategy [2] - A high-definition video webcast of the presentation will be available the following day and archived for 90 days [3]

Core Insights - Ocugen, Inc. is set to host a conference call and live webcast on November 5, 2025, at 8:30 a.m. ET to discuss its third quarter 2025 financial results and provide a business update [1] - The company will issue a pre-market earnings announcement on the same day, with details for participation provided [2] - Ocugen is recognized as a leader in biotechnology, focusing on gene therapies for blindness diseases, utilizing a modifier gene therapy platform to address complex diseases caused by imbalances in multiple gene networks [3] Company Overview - Ocugen, Inc. specializes in gene therapies for blindness diseases, with a focus on inherited retinal diseases such as retinitis pigmentosa, Stargardt disease, and geographic atrophy [3] - The company's approach is gene-agnostic, aiming to meet significant unmet medical needs for large patient populations [3]

Core Viewpoint - Ocugen, Inc. has entered into a securities purchase agreement with Janus Henderson Investors to raise capital through a registered direct offering of common stock and warrants, aiming to enhance its financial position for ongoing gene therapy developments for blindness diseases [1][3]. Group 1: Offering Details - The company will sell 20,000,000 shares of common stock at a price of $1.00 per share, with warrants to purchase an additional 20,000,000 shares at an exercise price of $1.50 per share [1][3]. - The gross proceeds from the offering are expected to be approximately $20 million, with potential additional proceeds of up to $30 million if the warrants are fully exercised [3]. - The offering is expected to close on or about August 11, 2025, subject to customary closing conditions [3]. Group 2: Company Background - Ocugen, Inc. is a biotechnology leader focused on gene therapies for blindness diseases, utilizing a modifier gene therapy platform to address complex diseases caused by imbalances in multiple gene networks [5]. - The company is developing programs for inherited retinal diseases and other blindness conditions affecting millions globally, including retinitis pigmentosa and Stargardt disease [5].